From Advocacy to Access: Mito Community Celebrates FDA Milestone
Barth syndrome therapy sets precedent for future treatments targeting mitochondrial dysfunction In a landmark decision, the U.S. Food and Drug […]
Latest News
IMP Launches New TK2d Video
IMP Launches New TK2d Video To mark TK2d Awareness Day 2025, we’ve released a new video that amplifyies the voices
IMP Welcomes Three New Members
IMP now has members across three continents We’re delighted to welcome three new members to IMP. With these new members,
Landmark Success for Mitochondrial Donation: A Milestone for Families Worldwide
The birth of eight healthy babies in the UK through mitochondrial donation (also known as Mitochondrial Replacement Therapy) has been
IMP Announces New Board Following Election
IMP is delighted to announce the results of its recent Board elections, confirming a dynamic and diverse leadership team that
Scientists provide first evidence that the drug sildenafil may benefit patients with Leigh syndrome, and particularly those carrying mutations in the mitochondrial gene MT-ATP6.
Primary Mitochondrial Myopathies: Patient Journey
Navigating the journey to gain a diagnosis of Primary Mitochondrial Myopathy can be unnecessarily long, intensely stressful, and fraught with obstacles.
Countdown to Rare Disease Day 2025!
The countdown is on to Rare Disease Day 2025 which takes place on 28 February.
Collaboration with MITGEST
IMP is proud to support MITGEST. This international consortium brings together world-class academic experts in mitochondrial research.
SIMPATHIC project prepares to launch clinical trial
The SIMPATHIC project is preparing to launch a clinical trial using Sildenafil as a potential treatment for Leigh syndrome.